ACIU
AC Immune S.A.
ACIU's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over ACIU overall, supported by stronger fundamentals and lower modeled downside.
ACIU Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
ACIU's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ACIU PE Valuation
ACIU has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ACIU Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect ACIU to return to profit, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ACIU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.52 | +$0.08 |
| Q1 2026 | -$0.79 | -$0.16 |
| Q4 2025 | -$0.84 | -$0.23 |
| Q3 2025 | -$0.85 | -$0.35 |
| Q2 2025 | -$0.60 | +$0.18 |
| Q1 2025 | -$0.63 | +$0.11 |
| Q4 2024 | -$0.61 | +$0.17 |
| Q3 2024 | -$0.50 | +$0.48 |
ACIU is still losing money, but far less than before: $0.52 per share over the past year, against $1.23 at its worst in mid-2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ACIU on earnings quality, reporting a profit while its opponent remains loss making.
ACIU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $18.2M | +1057% |
| Q1 2026 | $1.3M | +13% |
| Q4 2025 | $406.9K | -70% |
| Q3 2025 | $1.1M | -96% |
| Q2 2025 | $1.6M | +90% |
| Q4 2024 | $1.4M | -92% |
| Q4 2023 | $17.8M | +1479813% |
| Q4 2020 | $1.1M | +9.8% |
ACIU's revenue is recovering but still below its 2019 peak: $18M last quarter, up 1057% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 7.9% | +1492 points |
| Q1 2026 | -1322% | +635 points |
| Q4 2025 | -4262% | -2625 points |
| Q3 2025 | -1722% | -1750 points |
| Q2 2025 | -1485% | +1567 points |
| Q1 2025 | -1957% | N/A |
| Q4 2024 | -1637% | -1614 points |
| Q3 2024 | 29% | N/A |
ACIU's operating margin was 7.9% last quarter, up 1492 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ACIU on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ACIU on profitability, with a higher operating margin.
ACIU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | +$19.2M |
| Q1 2026 | $0 | +$23.1M |
| Q4 2025 | -$19.9M | -383% |
| Q3 2025 | -$22.1M | -$4.9M |
| Q2 2025 | -$19.2M | -122% |
| Q1 2025 | -$23.1M | -2575% |
| Q4 2024 | $7M | +$26.7M |
| Q3 2024 | -$17.2M | -$881.2K |
ACIU has burned cash in most quarters: −$42M over the past year, against −$53M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ACIU on cash generation, producing positive trailing cash flow while its opponent burns cash.
ACIU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -1.9% | -2M shares |
| 3 years | +17% | +14.5M shares |
| 5 years | +34% | +25M shares |
| Available history | +37% | +26.4M shares |
ACIU has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $6,019 |
| Q4 2024 | — |
| Q3 2024 | — |
ACIU hasn't bought back shares in the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ACIU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2019 | -4.3x | Net Cash |
| Q3 2019 | -4.3x | Net Cash |
ACIU has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ACIU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.0 | Neutral |
| Stochastic | 18.0 | Oversold |
ACIU's weekly RSI is 40 (neutral) and its Stochastic is 18 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ACIU PE vs Healthcare Sector
| Metric | ACIU | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ACIU has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ACIU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.39 | 10% below |
| 20 week MA | $2.47 | 13% below |
| 50 week MA | $2.74 | 22% below |
| 100 week MA | $2.57 | 17% below |
| 200 week MA | $2.81 | 24% below |
ACIU is in a downtrend: it's below all five of its weekly moving averages, and 24% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ACIU on trend strength, trading above more of its moving averages.
ACIU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.39 | $5.51 | -34% |
| 2021 | $5.51 | $5.39 | -2.2% |
| 2022 | $5.39 | $1.75 | -68% |
| 2023 | $1.75 | $5.00 | +186% |
| 2024 | $5.00 | $2.73 | -45% |
| 2025 | $2.73 | $3.13 | +15% |
| 2026 YTD | $3.13 | $2.14 | -32% |
ACIU's yearly returns have swung widely, from +186% in 2023 to −68% in 2022. It's down 32% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ACIU on returns for 2026, with the stronger performance.